-
More than $350 million is up for grabs for health care organizations aiming to create innovative care models that provide better care for less money, and in early July, the Department of Health and Human Services announced the latest round of prospective recipients.
-
For many years, the IRB office at Childrens Hospital Los Angeles (CHLA) followed a process that was standard at most institutions: long, regularly scheduled meetings organized to review an ever-increasing number of protocols.
-
As IRB offices gear up for a busy academic research year, its a good idea to dust off IRB templates, checklists, and other tools to revise, improve, and adapt to technology and other changes.
-
Evaluating research risk requires understanding a variety of potential harms and their nuanced impact. IRBs might find it useful to have a matrix to help explore each potential harm.
-
Even as multicenter studies with central IRB reviews gain traction, some IRBs are still hesitant to join in. However, coordinating a multisite study among several IRBs within the same university system can be a time and paperwork hassle for both principal investigators and IRBs and could make previously reluctant IRBs consider a new central reliance agreement.
-
The Presidential Commission for the Study of Bioethical Issues May 2014 report, Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society, includes recommendations for institutions and individuals engaged in neuroscience research.
-
Technology advances have driven increased interest in molecular studies involving tissue analyses. As a result, biotech firms increasingly are asking scientists to sell human tissues for study by outside enterprises.
-
The IRB at Grand Valley State University in Allendale, MI, uses a matrix that clarifies how IRB members and staff might describe various potential harms at four levels, from no more than minimal risk to high risk.
-
In this retrospective study of extubation outcomes in five ICUs at a single medical center, patients extubated at night had no increase in adverse events and their mortality rates and lengths of ICU stay were lower.
-
Mean daily doses of up to 40 mg of prednisone equivalents and lengthy ICU stays were associated with impaired physical outcomes in patients who survived acute lung injury.